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created stable isogenic prostate cancer cell lines overexpressing TWIST1 wild-type, phospho-mutants, and tethered
versions.Weassessed these isogenic lines using assays thatmimic stagesof cancermetastasis. In vitro assays suggested
the phospho-mimetic Twist1-DQDmutation could confer cellular properties associated with pro-metastatic behavior. The
hypo-phosphorylation mimic Twist1-AQA mutation displayed reduced pro-metastatic activity compared to wild-type
TWIST1 in vitro, suggesting that phosphorylation of the TWIST1 TQSmotif was necessary for pro-metastatic functions. In
vivo analysis demonstrates that the Twist1-AQAmutation exhibits reduced capacity to contribute to metastasis, whereas
the expression of the Twist1-DQD mutation exhibits proficient metastatic potential. Tethered TWIST1-E12 heterodimers
phenocopied the Twist1-DQD mutation for many in vitro assays, suggesting that TWIST1 phosphorylation may result in
heterodimerization in prostate cancer cells. Lastly, the dual phosphatidylinositide 3-kinase (PI3K)-mammalian target of
rapamycin (mTOR) inhibitor BEZ235 strongly attenuated TWIST1-inducedmigration thatwas dependent on the TQSmotif.
TWIST1 TQS phosphorylation state determines the intensity of TWIST1-induced pro-metastatic ability in prostate cancer
cells, which may be partly explained mechanistically by TWIST1 dimeric partner choice.
Neoplasia (2015) 17, 16–31Introduction
Prostate cancer is diagnosed in one of sixmen in theUnited States,making
it the most common cancer diagnosed in men and the second leading
cause of cancer deaths in men [1]. The natural history of prostate cancer
suggests that understanding mechanisms of disease progression from
localized tometastatic disease will result in the largest therapeutic gains [2].
One cellular pathway bywhich cancer cellsmay become pro-metastatic
is the epithelial-mesenchymal transition (EMT). EMT is a transcriptional
program, required during development and selectively silenced postna-
tally, that is reactivated in cancer cells to facilitate aggressive andmetastatic
behavior [3]. TWIST1 is a basic helix-loop-helix (bHLH) multidomain
transcription factor that binds to E-box– and D-box–regulated target
genes resulting in the elaboration of an EMT transcriptional program
[4–9]. TWIST1 functions as a dimer, either as a homodimer, TWIST1-
TWIST1 (T-T), or as a heterodimer with E2A proteins (E12/E47),
TWIST1-E12 (T-E), HAND proteins (HAND1/2), and likely other
bHLH superfamily members [7,9]. During development, TWIST1
dimer partner choice is, in part, regulated by the phosphorylation state of
a Thr-Gln-Ser (TQS) motif in helix I of the TWIST1 protein [9], and
human mutations inTWIST1 that disrupt TWIST1 phosphoregulation
are causative of the human autosomal dominant disease Saethre-Chotzen
syndrome [10,11]. These observations support a model where tight
regulation of the phosphorylation state and dimeric partner choice of
TWIST1 is essential for normal development.
The role of TWIST pathways in prostate cancer pathogenesis [12,13]
and in prostate cancer disease progression and metastasis is becoming
increasingly recognized as potentially important [14–18]. The critical
domains of TWIST1 and dimeric partner required for increased
tumorigenicity and aggressive metastatic phenotypes in prostate cancer
are understudied [16].Describing the functional significance of conserved
structural domains and identifying critical binding partners of TWIST1
will increase mechanistic insights that can facilitate precise inhibitory
strategies for TWIST1-induced cancer progression and metastasis.
Herein, we used a series of phosphorylation mutant and tethered
versions of TWIST1 to perform structure-function analysis with assays
that are surrogates for aggressive cellular and metastatic phenotypes in
prostate cancer cells. By using isogenic androgen-dependent, Myc-CaP[19], and androgen-independent, PC3, cell lines overexpressing
TWIST1 or phospho-mutant versions, we demonstrated specific
requirements for TWIST1 TQS phosphorylation during TWIST1-
induced metastasis of prostate cancer cells in vitro and in vivo. The dual
ATP-competitive phosphatidylinositide 3-kinase (PI3K) and mamma-
lian target of rapamycin (mTOR) inhibitor BEZ235 suppressed
TWIST1-induced cellular migration. Finally, comparison of the TQS
phospho-mutants with tethered TWIST1 overexpressing cells, T-T and
T-E, suggested that TWIST1 TQS phosphorylation may be one factor
resulting in T-E heterodimerization in prostate cancer cells.
Materials and Methods
Plasmids, Antibodies, and Reagents
pBABE-TWIST1-puro [20] was used to construct the Twist1-AQA
andTwist1DQDmutant constructs using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene, San Diego, CA) and confirmed by
sequencing. The following antibodies were used: Twist (Twist2C1a)
(sc-81417; SantaCruz Biotechnology,Dallas, TX), E-cadherin (ab53033;
Abcam, Cambridge, UK), vimentin (ab92547), ZO-1 (5406; Cell
Signaling Technology, Beverly, MA), β-actin (A5316; Santa Cruz
Biotechnology), c-Myc (N-term) (1472-1; Epitomics, Burlingame, CA),
HRP-conjugated secondary antibodies (Invitrogen, Carlsbad, CA), and
Alexa Flour 488–conjugated secondary antibodies (Invitrogen). BEZ235
was purchased from Selleckchem, Houston, TX (S1009).
Clone 2088/2089 (tethered Flag–T-E) and 2411 (tethered Flag-
TWIST1-Flag-TWIST1) [21] tethered open reading frames were
excised from the parental plasmid withHindIII and XbaI digestion, and
the ends were made blunt with T4 DNA polymerase and subcloned
into pBABE-puro retroviral vector into blunt ended EcoR1 sites. The
directionality of the clones was confirmed by restriction digestion. A
similar procedure was performed to clone these open reading frames
into the multiple cloning sites of the lentiviral vector W118.
Cell Line and Culture Conditions
PC3 and 22RV1 were obtained from American Type Culture
Collection (Manassas, VA). Myc-CaP was a kind gift from Dr John
18 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. Neoplasia Vol. 17, No. 1, 2015Isaacs (Johns Hopkins University [JHU]) [19]. Myc-CaP was grown in
Dulbecco's modified Eagle's medium (Invitrogen), PC3 inHams F12K
(Invitrogen), and 22RV1 in RPMI 1640 (Invitrogen). All media were
supplemented with 10% FBS, penicillin (100 units/ml), and
streptomycin (0.1 mg/ml). Cells were maintained at 37°C in a
humidified incubator with 5% CO2. Cell line identity was confirmedby short tandem repeat profiling, and mycoplasma tested.
Retroviral Experiments
We used ecotropic and amphotropic Phoenix packaging lines for
retroviral production. Myc-CaP and PC3 cells were transduced with
pBABE-Puro vector constructs for two successive times over a 36-hour
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at 80% confluence. Stable cell lines were made by pooling the selected
colonies. All cell lines were maintained under antibiotic selection.
Luciferase Promoter Reporter Assay
Subconfluent cells were transfected using Lipofectamine 2000
(Invitrogen) with 200 ng of firefly luciferase reporter gene construct
(100 ng was used for SNAI2 reporter assays), 100 ng of the pRL-SV40
Renilla luciferase construct, and 500 ng of the TWIST1 or TWIST1
phospho-mutant expression constructs. Cell extracts were prepared
36 hours after transfection in passive lysis buffer, and the reporter
activity was measured using the Dual Luciferase Reporter Assay
System (Promega, Madison, WI).
Wound-Healing Migration Assay
Two-dimensional migration assay was performed using a scratch/
wound model. Cells were grown in six-well plates for 24 hours to
confluence. Multiple scratch wounds were created using a P-20
micropipette tip, and cells were fed with fresh complete media. Five
representative fields of the wound were marked and images were
taken at 0 and 24 hours after wounding. Relative wound closure is
calculated from the remaining wound area normalized to the initial
wound area using ImageJ software (NIH Image, Bethesda, MD).
BEZ235 experiments involved pre-treatment for 24 hours before
creating scratch wounds and then proceeded as above.
Biophysical Assays
Fourier transform traction microscopy was used to measure the
contractile stress arising at the interface between each adherent cell and
its substrate as described [16]. Briefly, cells were plated sparsely on
elastic gel blocks coated with type I collagen. Images of fluorescent
microbeads (0.2 μm in diameter; Molecular Probes, Eugene, OR)
embedded near the gel apical surface were taken before and after cell
detachment with trypsin. The fluorescent image of the same region of
the gel after trypsin was used as the reference (traction-free) image. The
displacement field between a pair of images was then obtained by
identifying the coordinates of the peak of the cross-correlation function
[22,23]. From the displacement field and known elastic properties of
the gel (Young’s modulus of 1 kPa with a Poisson’s ratio of 0.48), the
cell traction field was computed. The computed traction field was used
to obtain net contractile moment, which is a scalar measure of the cell’s
contractile strength, expressed in pico-Newton meters (pNm).Figure 1. Phosphorylation of the TWIST1 TQS motif is required for TW
(A) A schematic of TWIST1 protein structure and the position 125 thre
Twist1-AQA and Twist1-DQD (this schematic is not to scale). The posi
above the sequence. A red bar below the sequence delineates a PKA
expression in (B) Myc-CaP and (C) PC3 cells stably expressing Vector
mutants with β-actin used as a loading control. The ~25 kDa band is
may be a degradation product or a posttranslationally modified version
DQDmutant is proficient, but the Twist1-AQAmutant is defective for t
transiently transfected with expression vectors for the firefly lucifer
Renilla luciferase reporter vector for normalization of transfection effic
Renilla activity and showed that TWIST1 and Twist1-DQD overexpress
the Twist1-AQA mutant was defective for this function. (E) Similar rep
construct and showed that the Twist1-AQA mutant had no ability to tr
DQD overexpression. Each bar represents values from at least three
column mean; error bars ± SEM. Paired two-tailed t test; *P b .05, **P
also assessed by Western blot analysis for E-cadherin and vimentinMatrigel Invasion Assay
The invasion potential was assessed usingChemicon cell invasion assay
kit (Millipore, Billerica,MA) as directed by themanufacturer. Transwells
with 8μMpores coated withMatrigel were used for the assay. Serum-
starved (0.5 × 106 to 1 × 106) cells (12-16 hours) in 300μl of 10%FBS
complete mediumwere seeded in the upper chambers, while lower wells
were filled with 500 μl of 10% FBS complete medium. Invading cells
on the lower surface were fixed and stained. The stain was dissolved in
200 μl of 10% acetic acid andmeasured at 570 nm. Invasive potential is
derived by normalizing with the readings from blank transwell inserts.
Immunohistochemistry and Western Blot Analysis
Immunohistochemistry (IHC), Immunofluorescence (IF), and
Western blot analysis were performed as described previously [24].
Anoikis Assay and Apoptosis Assessment
Anoikis resistance was measured using a modified protocol [25]. Cells
were grown in normal attachment and ultra-low attachment (Corning
Inc, Corning, NY) six-well plates. Twenty-four hours later, cells were
blocked in 5% FBS and stained with Alexa Fluor 488–conjugated
Annexin V followed by propidium iodide (PI) staining (50 μg/ml;
Invitrogen). Cells were enumerated on a BD FACSCalibur (BD
Biosciences, San Jose, CA), and analysis was done using FloJo analysis
software. All conditions were n = 4 and two replicates per experiment.
Clonogenic Survival Assay and Soft Agar Colony Formation Assay
Clonogenic survival was performed as previously described [26].
Soft agar clonogenic assays used six-well plates pre-coated with 1 ml
of basal 0.6% agarose in complete media and overlaid with 2 ml of
cells (5 × 103 cells/ml) mixed with 0.3% agarose in complete media and
allowed to solidify. The wells were constantly fed with complete media
to prevent drying of agarose, and then after 10 to 15 days of incubation,
colonies were scored under phase contrast microscopy. All conditions
were repeated at least twice with three wells per experiment.
Animal Models and Histology
All procedures were carried out in accordance with the Johns Hopkins
Animal Care and Use Committee, maintained under pathogen-free
conditions, and given food and water ad libitum. For the experimental
lung metastasis assay, 100 μl of phosphate-buffered saline containing
5 × 105 cells were injected into athymic nude mice through the tail
vein. After 4 weeks, the mice were sacrificed, and necropsies were
performed to score surface lung tumors and extra-thoracic metastases.IST1-induced EMT cellular marker profile in prostate cancer cells.
onine (T125) and 127 serine (S127) site-specific mutants examined
tion of the basic domain (in blue) and helix I are represented by bars
recognition site. Western blot analysis was performed for TWIST1
and overexpressing similar levels of TWIST1 or TWIST1 phospho-
the dominant TWIST1 immunoreactive species. The smaller band
of Twist1. TWIST1 promoter reporter assays show that the Twist1-
ranscriptional regulation of EMTmarker genes. Myc-CaP cells were
ase-linked (D) E-cadherin gene (CDH1) promoter construct and a
iency. After 36 hours, cell extracts were assayed for luciferase and
ion repressed transcription from the E-cadherin gene promoter, but
orter assays were performed using a SLUG gene (SNAI2) promoter
ansactivate transcription compared to wild-type TWIST1 or Twist1-
independent experiments performed in triplicate. Bars represent
b .01, and ***P b .001. Epithelial and mesenchymal markers were
in (F) Myc-CaP and (G) PC3 cells.
Figure 2. The TWIST1 phospho-null TQSmotifmutation is defective formigration inMyc-CaP prostate cancer cells. (A) Representative phase
contrast images of Myc-CaP cells overexpressing TWIST1 and TWIST1 phospho-mutants directly following and 24 hours after wound
scratch. (B) Relative wound closure is calculated by the remaining wound area normalized to the initial wound area [n≥ 3 experiments with
three fields per experiment by ImageJ software (NIH)] and showed that Myc-CaP cells overexpressing Twist1-AQAwere less migratory than
wild-type TWIST1 and Twist1-DQDcells.Mann-Whitney test: *Pb .05, **Pb .01, and ***Pb .001. (C) TWIST1overexpression increases single
prostate cancer cell traction forces on the substratum, which is attenuated by the Twist1-AQAmutation. The cell traction forces for individual
cells (n = 20) are measured by using Fourier transform traction microscopy. The top panel shows representative phase contrast images of
Myc-CaP isogenic cells. The bottom panel shows the tractionmaps; the colorswithin the cells represent the absolutemagnitude of tractions
in Pascal, and the arrows represent the relativemagnitude and directions. (D) TWIST1 and Twist1-DQDmutant overexpression increases the
mean of the projected area represented in bar graph format, and the Twist1-AQA phospho-mutant isogenic cell line is defective for this
phenotype. (E) TWIST1 and Twist1-DQDmutant overexpression increases cell traction force exerted by a single living cell, or net contractile
moment, and the Twist1-AQAmutant is completely deficient for this function. Bars represent columnmean; error bars are±SEM. The values
are significant by Mann-Whitney test: *P b .05, **P b .01, and ***P b .001.
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Microarrays were performed using GeneChip WT cDNA Synthesis
and Amplification Kit and WT Terminal Labeling Kit (Affymetrix,
Santa Clara, CA). The labeled ssDNA was hybridized to the GeneChipMouse Gene 1.0 ST Array (Affymetrix), washed with the Fluidics
Station 450, and performed array scanning as previously described [27].
Arrays were normalized using the RobustMultichip Average in the oligo
Bioconductor package at the transcript level [28]. Genes and gene sets
Figure 3. Phosphorylation of the TWIST1 TQS motif is required for TWIST1-induced invasion in prostate cancer cells. Transwell invasion
assayswithMatrigel were performedwith isogenic (A) Myc-CaP (n=10) and (B) PC3 cells (n=6). TheMyc-CaP cells were allowed to invade
for 24 hours and PC3 cells for 60 hours. TWIST1 and Twist1-DQDoverexpression increased invasion intoMatrigel for bothMyc-CaP and PC3
cells, but theTwist1-AQAmutantwasnomore invasive thanVector (representedbycolumnmean±SEM;*Pb .05, **Pb .01, and ***Pb .001
by paired two-tailed t test).
Neoplasia Vol. 17, No. 1, 2015 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. 21with Benjamini-Hochberg [29] P values below .05 were considered
statistically significant. Gene set enrichment analysis was performed
using the C2 Curated Gene Sets collection from the Molecular
Signature Database 3.0 and statistical comparisons by Fisher exact test.
The microarray data have been deposited to the Gene Expression
Omnibus (GSE500002).
SYBR Green Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA was isolated from cells using the QIAprep RNeasy Kit
(Qiagen, Carlsbad, CA) or Trizol (Life Technologies, Carlsbad, CA)
according to the manufacturer’s directions. Samples were treated with
RQ1 RNase-Free DNase (Promega). The cDNA was generated from 1
μg of total RNA using the Superscript II Kit (Invitrogen Technologies).
Control reactions were run without reverse transcription enzyme. Fifty
nanograms of cDNA equivalents was amplified for the transcript
described below in an ABI Prism 7900 HT for 40 cycles using SYBR
Green PCRMasterMix (PerkinElmer Applied Biosystems, Foster City,
CA). Polymerase chain reactions (PCRs) were performed in duplicate/
triplicate in a final volume of 20 μl. Following amplification, the data
were processed with the analysis program Sequence Detection Systems
v2.2.2 (PerkinElmer Applied Biosystems). For each sample, the level
of RNA for the genes of interest was standardized to a housekeeping
gene (ubiquitin or 18S rRNA) within that sample; subsequently, the
level of the transcript of interest was normalized to the expression of
that transcript from the appropriate comparator sample. Primers for
quantitative PCR were reported previously.
Statistical Analyses
Statistical analysis was carried out using GraphPad Prism
version 5.04 for Windows (GraphPad Software, La Jolla, CA).
Pairwise comparisons were tested using the paired two-tailed t test,
Mann-Whitney test, or Fisher exact test. P values b .05 were consideredstatistically significant, and throughout this study, *P b .05, **P b .01,
and ***P b .001.
Results
Study Rationale
The TWIST1 bHLH domain can be phosphorylated at the Thr125-
Gln-Ser127 (TQS) motif (Figure 1A). TWIST1 TQS phosphorylation
state has been shown to direct TWIST1 dimerization with selective
preference for TWIST1 to form T-T homodimers or E12 to form T-E
heterodimers [30,31], but the significance of these phosphorylation states
for TWIST1-induced phenotypes in cancer such as metastasis is
unknown. Cancer cell metastasis is the culmination of sequential cellular
actions that include loss of cell-to-cell adhesion, migration and invasion
into the local extracellular matrix, intravasation into the vasculature,
resistance to anoikis, extravasation into the parenchyma of distant tissues,
and then colonization into amacroscopicmetastatic tumor [32]. To assess
the significance of the phosphorylation state of the TQS motif for cancer
cell metastasis, we generated site-specific TWIST1mutations at the TQS
motif to create hypo-phosphorylation mimetic (Twist1-TQS125AQA)
and phospho-mimetic (Twist1-TQS125DQD) versions, referred to as
Twist1-AQA and Twist1-DQD, respectively (Figure 1A). We then
established stable isogenic cell lines expressing TWIST1, Twist1-AQA,
and Twist1-DQD in Myc-CaP and PC3 prostate cancer cells to
determine the requirement of TQS motif phosphorylation for these
metastatic steps using in vitro and in vivo assays (Figure 1, B and C ). We
next examined the requirement of phosphorylation on theTWIST1TQS
motif by the PI3K-AKT-mTOR pathway for cell migration using a
specific dual PI3K-mTOR small molecule inhibitor. Finally, we created
isogenic Myc-CaP lines that overexpressed tethered versions of T-T and
T-E dimers and compared them to the TWIST1 phospho-mutant lines
to determine the possible functional significance of TQS phosphorylation
on TWIST1 dimer preference for cancer cell metastasis.
Figure 4. The Twist1-AQA mutant is defective for TWIST1-induced soft agar tumorigenicity. Cells were grown adherent or in suspension
using ultra-low attachment dishes. The amount of apoptotic cell death or anoikis for the ultra-low attachment conditions was quantified by
Annexin V–Alexa Fluor 488 and PI staining followed by flow cytometric analysis. Percent apoptosis was calculated by normalizing total
apoptotic fraction in ultra-low attachment conditions to that of adherent cells and plotted as bar graph ± SEM for (A) Myc-CaP (n= 7) and
(B) PC3 (n= 6) TWIST1 isogenic cell lines (*P b .05, **P b .01, and ***P b .001 by paired two-tailed t test); 5 × 105 cells were embedded in
soft agar and incubated for 2 weeks. Colonies containing more than 50 cells were scored in at least five random fields. Representative
phase contrast images of (C) Myc-CaP and (D) PC3 TWIST1 isogenic cell lines at ×4 magnification are shown. The percent clonogenicity
in soft agar is calculated by normalizing the number of colonies to the total number of cells and represented as bar graphs ± SEM for
(E) Myc-CaP (n = 6) and (F) PC3 (n = 6) (*P b .05, **P b .01, and ***P b .0001 by Mann-Whitney test).
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Induce EMT Markers
In Myc-CaP prostate cancer cells, transient overexpression of
TWIST1 and the Twist1-DQD mutant showed repression of CDH1
(Figure 1D, P b .001 compared to Vector control) and activation of
SNAI2 (Figure 1E, P b .05 compared to Vector control) promoter
activity (Figure 1, D and E, both P b .001 compared to Vector
control). Interestingly, Twist1-AQA was found to be defective for both
repression and activation in these assays and was not significantly
different from the Vector control (Figure 1,D and E, P N .05 for both).These results suggest that phosphorylation of the TQSmotif is required
for TWIST1 transcriptional regulation of EMT marker genes.
Stable TWIST1 and Twist1-DQD overexpression led to down-
regulation of the epithelial marker E-cadherin and up-regulation of
the mesenchymal marker vimentin in Myc-CaP and PC3 cells
(Figure 1, F and G). In both Myc-CaP and PC3 cells, the phospho-
null mutation, Twist1-AQA, was unable to downregulate E-cadherin
or upregulate vimentin (Figure 1, F and G). Taken together, these
findings suggest that phosphorylation of the TQS motif is required
for TWIST1 to induce EMT phenotype in prostate cancer cells.
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TWIST-Induced Pro-Metastatic Cellular Behaviors
We then directly assessed the requirement of TQS motif
phosphorylation of TWIST1 for conferring pro-metastatic behaviors
to prostate cancer cells. The Twist1-AQA mutation appeared to
inhibit the migration phenotype of these cells as results were no
different than those observed using the Vector control (Figure 2, A
and B, P N .1). In contrast, Myc-CaP cells stably overexpressing
either TWIST1 or Twist1-DQD migrated faster than both Vector
control and Twist1-AQA expressing cells (Figure 2, A and B, all
pairwise comparisons P b .01). The Twist1-DQDmutation actually
conferred increased migration rate to Myc-CaP cells that exceeded
the rate of migration of cells expressing wild-type TWIST1 (Figure 2, A
and B, P b .05).
Cell migration necessitates contractile force generation by cells on
their surroundings. Using traction microscopy, we interrogated the
force generating capacity of single Myc-CaP overexpressing TWIST1cells (Figure 2C ). Compared with Vector control, the TWIST1 and
Twist1-DQD overexpressing Myc-CaP cells showed increased cell
spreading area and net contractile moment, a scalar measure of
cellular contractile strength (Figure 2, D and E, at least P b .05 for all
comparisons). The Twist1-AQA mutation overexpressing Myc-CaP
cells displayed less cell spreading and lower net contractile moment
compared to TWIST1 and Twist1-DQD (Figure 2, D and E, at least
P b .05 for all comparisons) and was indistinguishable from Vector
control cells (Figure 2, D and E, P N .1). The single cell biophysical
data corroborate our results obtained from the bulk migration assays.
Taken together, TWIST1 TQS phosphorylation is required for
increasing cytoskeletal force generation and migratory potential in
prostate cancer cells.
Myc-CaP and PC3 cells overexpressing TWIST1 and the
phospho-mimetic version of TWIST1 showed increased invasion
compared to Vector control and Twist1-AQA overexpressing cells
using a Matrigel-coated transwell invasion assay (Figure 3, A and B,
all pairwise comparisons at least P b .05). The hypo-phosphorylation
mimetic TWIST1 mutation was completely defective for conferring
TWIST1-induced invasion in Myc-CaP and PC3 cells and was
similar to Vector control cells (Figure 3, A and B, P N .3). Similar to
migration, the phosphorylation of TWIST1 TQS was required for
TWIST1-induced prostate cancer invasion.
The resistance to anoikis facilitates metastasis of cancer cells to distant
organs [32]. BothTWIST1 andTwist1-DQDoverexpressingMyc-CaP
and PC3 cells showed decreased apoptosis when grown in low
attachment conditions compared to their isogenic Vector control cellsFigure 5. Phosphorylation of the TWIST1 TQS motif is required for
TWIST1-inducedprostate cancermetastasis in vivo. The experimental
lungmetastasis assaywasperformedwithMyc-CaPTWIST1 isogenic
cell lines; 5× 105 cells were tail vein injected into 8-week-old athymic
nude male mice, sacrificed 4 weeks later and inspected for lung
colonization and extra-thoracic metastases. Cohorts of four to six
mice were used for each cell line and experiments were performed at
least twice. (A) Representative necropsy photographs with lung
tumors distinguished by black arrows and a large chest wall lesion in
the Twist1-DQD mouse identified with a white arrow. (B) A
contingency table comparing the ability of the three isogenic cell
lines to colonize lung tumors in vivo fromA. TWIST1 and Twist1-DQD
overexpressing Myc-CaP cells are able to form macroscopic lung
tumors in vivo at a much higher frequency than Vector control cells
(P b .01 for both comparisons by Fisher exact test). The Twist1-AQA
box mutant Myc-CaP cells had an intermediate phenotype in vivo
(P=1 compared toVector;P= .0662compared towild-type TWIST1;
and P = .0894 compared to Twist1-DQD by Fisher exact test).
(C) Representative necropsy photographs of extra-thoracic metasta-
ses from mice injected with TWIST1 isogenic cells with metastases
indicated by black arrows. These extra-thoracic metastases represent
the consequence of prostate cancer cells undergoing the full
metastatic pathway following tail vein injection. (D) A contingency
table comparing the ability of the three isogenic Myc-CaP cell lines to
form extra-thoracic metastases from C. TWIST1 and Twist1-DQD
overexpression conferred Myc-CaP cells with the ability to form extra-
thoracicmetastases at a higher frequency than Vector control cells and
the Twist1-AQA mutant overexpressing cells (P b .05 for TWIST1 vs
Vector; P b .05 for TWIST1 vs Twist1-AQA; P b .001 for Twist1-DQD vs
Vector; and P b .001 for Twist1-DQD vs Twist1-AQA by Fisher exact
test). (E) Representative anti-Myc IHC images of lungs or extra-thoracic
metastases isolated from mouse tail vein injected with Myc-CaP +
Vector cells (left) orMyc-CaP+Twist1-DQD(right twopanels). The lung
tumors (middle) and extra-thoracic metastasis (right panel) stained
positive for c-Myc, confirming that the tumor cells wereMyc-CaP cells.
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and B). Interestingly, the Twist1-AQA overexpressing Myc-CaP and
PC3 cells were able to resist anoikis more than Vector control cells
(Figure 4, A and B, both cell lines P b .01 vs Vector, and Figure S1, A
and B), suggesting that TQS phosphorylation is not absolutely requiredfor TWIST1-induced anoikis resistance. However, using clonogenic
survival assays, we did observe that the phosphorylation of the TQS
motif was required to confer radioresistance to prostate cancer cells
(Figure S2,A and B). These data suggest that, although phosphorylation
of the TWIST1 TQS motif is not generally required for resistance to all
Neoplasia Vol. 17, No. 1, 2015 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. 25cell death signals, phosphorylation of the TQS motif is required for
resistance to radiation-induced cell death in prostate cancer cells.
The anchorage-independent clonogenicity ofMyc-CaP andPC3 cells
stably overexpressing TWIST1 and the TWIST1 mutations was
performed (Figure 4, C–F ). Both TWIST1 overexpressing Myc-CaP
and PC3 cells showed increased frequency of colonies in soft agar
compared to their isogenic Vector control cells (Figure 4, C–F, both
cells P b .01). Myc-CaP and PC3 Twist1-AQA overexpressing cells
exhibit a decreased ability to form colonies in soft agar (Figure 4, C–F ).
The Twist1-DQD overexpressing Myc-CaP and PC3 cells formed
more colonies in soft agar than even wild-type TWIST1 (Figure 4,C–F,
P b .05). In addition, Myc-CaP cells overexpressing Twist1-DQD
formed larger sized colonies (Figure 4C ). These results with anchorage-
independent clonogenicity were confirmed within another prostate
cancer cell line, 22Rv1, which also stably overexpressed TWIST1 and
Twist1 phospho-mutant versions (Figure S3). Collectively, these data
confirm the importance of phosphorylation of the TQS motif for
aggressive in vitro prostate cancer cell behavior induced by TWIST1.
TWIST1 Phosphorylation Is Required for TWIST1-Induced
Prostate Cancer Metastasis In Vivo
The last and arguablymost important step in themetastatic cascade is
the colonization of a distant site and growth into a macroscopic
metastatic tumor. The potential of wild-type TWIST1 and TWIST1
TQS phospho-mutant overexpressing Myc-CaP cells to colonize and
form macrometastatic tumors in vivo was assessed using the
experimental lung metastasis assay. TWIST1 overexpression signifi-
cantly increased the ability of Myc-CaP cells to colonize the lungs and
form macroscopic metastases in vivo (Figure 5, A and B, 12 of 22 mice
injected with TWIST1 overexpressing Myc-CaP cells vs 2 of 22 mice
with isogenic Vector control cells, P b .01). The TWIST1 hypo-
phosphorylation mimetic overexpressing Myc-CaP cells exhibited
greatly reduced potential to form macroscopic lung metastases in vivo,
and metastasis numbers were indistinguishable from Vector control
Myc-CaP lungs (Figure 5, A and B, 2 of 12 mice injected with Twist1-
AQA overexpressingMyc-CaP cells, P = 1 compared to Vector control;
P = .066 compared to TWIST1). Concordant with the in vitro assays
above, the TWIST1 phospho-mimetic overexpressing Myc-CaP cells
were able to form lung tumors similar to wild-type TWIST1 (Figure 5,
A and B, 7 of 12 mice injected with Twist1-DQD overexpressingMyc-
CaP cells vsTWIST1, P = 1; vsVector control, P b .01). The tumor cell
morphology from TWIST1 and TWIST1 phospho-mutant overex-Figure 6. TWIST1 global gene expression profiles are modulated b
expression analysis of Myc-CaP cells stably expressing Vector, TWIS
revealed a larger set of genes that were differentially expressed betw
the phospho-mutants and Vector control cells. Gene expression be
analysis of variance, and genes were considered differentially express
(B) Heat map visualization of supervised clustering analysis of gene
Twist1-AQA (AQA), and Twist1-DQD (DQD) shows that the TWIST1 p
profile. Each column represents a Myc-CaP microarray sample, and e
gene. High expression is indicated in green, intermediate expression
Curated Molecular Signatures database that were overrepresented (P
set of genes differentially regulated by TWIST1 but not by Twist1-A
prostate cancer cells overexpressing TWIST1 versus Twist1-AQA as
green and relative repression in red). Bottom table represents gene
transcriptome. (D) Summary of phenotypes for TWIST1 and the TW
T, TWIST1; AQA, Twist1-AQA mutant; DQD, Twist1-DQD mutant; Vepressing cells was similar (data not shown). In combination with
observations obtained in the in vitro assays, these data strongly support
that TWIST1 TQS phosphorylation is required for TWIST1-induced
prostate cancer cell colonization of macroscopic metastases in vivo.
Cells injected into the venous circulation seed the lungs preferentially
and any extra-thoracic metastases produced using this assay must
undergo the full metastatic pathway [33]. TWIST1 overexpression
significantly increased the frequency of mice with extra-thoracic
metastases (Figure 5, C and D, 9 of 22 mice injected with TWIST1
overexpressing Myc-CaP cells compared to 2 of 22 mice with isogenic
Vector control cells, P b .05). Twist1-AQAMyc-CaP cells were unable
to give rise to extra-thoracic metastases (Figure 5,C andD, 0 of 12mice
injected with Twist1-AQA overexpressing Myc-CaP cells, P b .05
compared to TWIST1 and P = 1 compared to Vector control cells). The
Twist1-DQD overexpressing cells demonstrated increased numbers of
mice with extra-thoracic metastases, 9 of 12, compared to Vector
control (P b .001) and Twist1-AQA (P b .001). Twist1-DQD
overexpressing cells produced more mice with extra-thoracic metastases
than wild-type TWIST1 cells, which was not statistically significant but
trended toward statistical significance (P = .0796). The Myc-CaP
identity of lung tumors and extra-thoracic metastases was confirmed by
positive Myc IHC (Figure 5E ). These results show that the TQS motif
phosphorylation of TWIST1 is required for TWIST1-induced
metastasis of prostate cancer cells in vivo.
Gene Expression Profiling Reveals that Phosphorylation of the
TQS Motif Is Required for the Full TWIST1-Induced
Transcriptional Program
Global gene expression analysis was carried out with isogenic Myc-
CaP lines, and in each pairwise comparison, we found several genes
that were differentially expressed. Compared with Vector control,
TWIST1 overexpression altered the expression of 425 genes.
Overexpression of the Twist1-AQA and Twist1-DQD phospho-
mutants altered the expression of much fewer genes compared to
Vector control (Figure 6A). Overexpression of Twist1-AQA altered
the expression of 132 genes, and a substantial portion (57 of 132) of
these genes was also observed with TWIST1 overexpression in Myc-
CaP cells. Overexpression of Twist1-DQD altered the expression of
105 genes, of which 23 were also altered in TWIST1 overexpressing
Myc-CaP cells (Figure 6A). This expression pattern is consistent with
each of the TWIST1 phospho-mutants inducing a separate altered
transcriptional program, each of which is a derivative of the wild-typey mutations in the TQS motif in prostate cancer cells. (A) Gen
T1 (WT), Twist1-AQA (AQA), and Twist1-DQD (DQD) by microarra
een TWIST1 overexpressing cells and Vector control compared t
tween groups was performed by empirical Bayesian moderate
ed if B N 0 following Benjamini-Hochberg false discovery rate (FDR
expression from Myc-CaP cells expressing Vector, TWIST1 (WT
hospho-mutants have derivative wild-type TWIST1 gene expressio
ach row represents median-centered expression values for a singl
in black, and low expression in red. (C) Selected gene sets from th
b .05, one-way Fisher exact test, Benjamini-Hochberg FDR) in th
QA (top table) that is relevant to phenotypic differences betwee
demonstrated in this study (relative overexpression is indicated i
sets that were overrepresented in the Twist1-DQD versus TWIST
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Gene set enrichment analysis [34] was used to identify gene sets
that were lost in Twist1-AQA overexpressing Myc-CaP cells
compared to TWIST1. Many of the gene sets lost in the Twist1-
AQA overexpressing cells were related to phenotypes that we directlyassayed, and aggressive cellular behavior and metastasis were observed
with overexpression of TWIST1 but not Twist1-AQA (Figure 6C,
top table). At the same time, several gene sets related to
transformation and cancer aggressiveness were overrepresented in
the set of genes regulated by expression of Twist1-DQD compared to
Neoplasia Vol. 17, No. 1, 2015 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. 27TWIST1 (Figure 6C, bottom table). This observation is consistent
with the trend toward more aggressive cellular behavior, which we
observed in cells overexpressing Twist1-DQD. These findings are
highly suggestive of a transcriptional mechanism for the phenotypic
differences observed between prostate cancer cells overexpressing
TWIST1 and those overexpressing the phospho-mutants. A summary
of all in vitro and in vivo phenotypes resulting from stable
overexpression of TWIST1 and TWIST1 phospho-mutants is
shown in Figure 6D.
T-E Heterodimer Overexpression Phenocopies Phospho-Mimetic
Mutant Twist1-DQD Most Closely for Pro-Metastatic
Cellular Behaviors
Isogenic Myc-CaP lines that overexpressed tethered versions of
T-T and T-E dimers were constructed (Figure 7A). We then
analyzed these TWIST1 tethered lines using the in vitro assays
used to characterize the TWIST1 phospho-mutants above. Stable
T-T tethered overexpressing Myc-CaP cells were able to
upregulate vimentin but could not downregulate E-cadherin
(Figure 7B). In contrast, T-E tetheredMyc-CaP cells expressed amarker
profile consistent with induction of an EMT and, at least qualitatively,
was able to upregulate vimentin andmodestly downregulate E-cadherin
compared to wild-type TWIST1 (Figure 7B).
Comparison of the TWIST1 tethered and phospho-mutant cell
lines for a gene expression signature characteristic of Twist1-DQD
overexpression revealed that Twist1-DQD and T-E gene expression
profiles were the most similar based on hierarchal clustering
(Figure 7C ). Twist1-AQA was most similar to Vector control
(Figure 7C ), and consistent with the loss-of-function phenotype, this
phospho-null mutation displayed in most assays used in this study
(Figure 6D ). T-T overexpressing cells were the most dissimilar
compared to the other TWIST1 isoforms for the gene expression
signature (Figure 7C ). Thus, T-E dimer overexpression results in a
transcriptional program and EMT marker profile most similar to
Twist1-DQD overexpression in Myc-CaP cells.
We then assessed the TWIST1 tethered isoforms for pro-metastatic
capabilities in vitro. T-E overexpression resulted in increased migration
ofMyc-CaP cells compared toTWIST1 andVector control (Figure 7D,
P b .01 for pairwise, and Figure S4A). T-T and Vector control cells had
the same decreasedmigratory potential (Figures 7D and S4A). Similarly,
the invasive ability of T-E tethered cells was more than that of Vector
control (both P b .01), and T-T cells were similar to Vector control
(Figure 7E, P = .9). Neither T-T nor T-E tethered overexpressing cells
showed any resistance to anoikis compared to Vector control (Figure 7F,
P N .2, and Figure S4B). T-E overexpressing cells had the most abilityFigure 7. Tethered T-E overexpressing cells phenocopy Twist1-DQD
(A) Western blot analysis was performed for TWIST1 and E12 expres
similar levels of TWIST1 or tethered versions of TWIST1 with β-actin
were also assessed by Western blot analysis for E-cadherin and vi
induce an EMT. (C) Usingmicroarray gene expression profiling data (F
expression was chosen, and the expression of these genes was meas
cells overexpressing tethered and phospho-mutant TWIST1. Relat
overexpression and red indicating underexpression. To evaluate the de
performed using a complete linkage algorithm, and the results are repre
T-E are the most similar based on gene expression profiling. Tethere
TWIST1phospho-mutants overexpressing cells for (D)migration, (E) tran
growth in soft agar. For all these assays with the exception of anoikisfor anchorage-independent growth and increased the soft agar
clonogenicity of Myc-CaP cells more than even wild-type TWIST1
(Figure 7G, P b .05, and Figure S4C ). T-T overexpressing cells had a
slightly increased ability to allow Myc-CaP cell anchorage-independent
growth compared to Vector control (Figure 7G, P b .01). Although not
a universal correlation, our studies with the tethered TWIST1 isoforms
suggested that T-E heterodimers have phenotypes most similar to the
Twist1-DQD mutation (compare Figures 2–4 vs 7, D–G; five of six
phenotypes were concordant between T-E and Twist1-DQD).
Pharmacologic Inhibition of the PI3K-AKT-mTOR Pathway
Prevents TWIST1-Induced Prostate Cancer Cell Migration
During embryonic development, TWIST1 dimer preference is
regulated by protein kinase A (PKA) phosphorylation of the TQSmotif.
The oncogenic kinase Akt (also known as protein kinase B) is aberrantly
activated as part of the PTEN-PI3K-AKT-mTOR pathway in a
majority of prostate cancer samples.We treated isogenicMyc-CaP lines
stably overexpressing TWIST1 and the isoforms used above with the
highly specific PI3K-mTOR dual kinase inhibitor BEZ235 (10 nM)
and assayed for effects on TWIST1-induced cellular migration.
BEZ235 is reported to have an half maximal inhibitory concentration
(IC50) of 4 to 75 nM for different isoforms of PI3K (p110α/γ/δ/β) and
6 nM for mTOR.We observed inhibition of TWIST1-induced cellular
migration to background levels or similar to Vector control cells with
24-hour pre-treatment with BEZ235 (Figure 8, A–C, P b .01).
Interestingly, the increased cell migration observed in Myc-CaP cells
overexpressing the Twist1-DQD phospho-mimetic mutant was not
inhibited by BEZ235 treatment (Figure 8, A–C ). As expected,
migration by Myc-CaP cells overexpressing the Twist1-AQA phos-
pho-null mutant was not affected by BEZ235 treatment (Figure 8, A–
C ). These effects on cell migration were not due to decreased cell
viability or proliferation of TWIST1-overexpressing cells following
BEZ235 treatment (Figure S5A). Similar results were observed when
treating Myc-CaP cells stably expressing the tethered versions of
TWIST1 (Figures S6,A–C, and S5B). Importantly, inhibition of PI3K-
mTOR kinase activity did not prevent the T-E isoform from increasing
TWIST1-induced cell migration (Figure S6, A–C ), similar to Twist1-
DQD. Together, these studies suggested that the PI3K-AKT-mTOR
pathway phosphorylated TWIST1 on the TQSmotif in prostate cancer
cells and that this site-specific phosphorylation was required for
TWIST1-induced prostate cancer cell migration.
Discussion
The functional significance of many of the TWIST1 orthologous
structural domains for animal development has been well studiedmutant overexpressing cells for pro-metastatic behaviors in vitro.
sion in Myc-CaP cells stably expressing Vector and overexpressing
used as a loading control. (B) Epithelial and mesenchymal markers
mentin. Tethered T-E overexpressing Myc-CaP cells were able to
igure 6), a gene expression signature characteristic of Twist1-DQD
ured by reverse transcriptase–quantitative PCR in isogenic Myc-CaP
ive expression is shown for each gene, with green indicating
gree of similarity between the samples, hierarchical clustering was
sented by the dendrogram. These data suggest that Twist1-DQDand
d T-T and T-E overexpressing cells were directly compared against
swell invasion, (F) anoikis resistance, and (G) anchorage-independent
resistance, T-E and Twist1-DQD cells were the most similar.
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the TWIST1 TQSmotif for cancer metastasis has not been reported.
Our study shows that phosphorylation of the TQS motif in helix I of
TWIST1 is required for induction of aggressive prostate cancer cell
behavior in vitro and, most importantly, for metastasis in vivo. One
possible conclusion from our data is that phosphorylation of this
TQS motif may result in heterodimerization of TWIST1 with E12
that enables elaboration of specific transcriptional programs that
produce a pro-metastatic cellular phenotype.
The TWIST1TQSmotif is highly conserved among the entire Twist
subclass of bHLH factors as distantly through evolution as insects, and
this domain is shown to be critical for the role of TWIST1 in
development and benign pathologic conditions as demonstrated by
transgenic mouse studies [21,30,31,37,38]. Moreover, nearby missense
mutations in the TQS region of TWIST1 cause the Saethre-Chotzen
syndrome, and these nearby mutations directly affect TWIST1 TQS
phosphorylation [10,11,31]. Mechanistically, during embryonic devel-
opment, PKA signal transduction pathways regulate TWIST1
dimerization preference and DNA binding by phosphorylation of this
highly conserved TQS motif [21,31]. At least for limb development,
TQS phosphorylation, or the equivalent Twist1-DQD mutation,
phenocopies tethered T-T homodimers, while the phospho-null
Twist1-AQA mutation has been shown to phenocopy tethered T-E
heterodimers [21]. The results of our current study suggest the inverse
correlation for prostate cancer cell metastasis. Specifically, Twist1-
DQD and tethered T-E appear to be the most similar for pro-metastatic
in vitro assays and by gene expression profiling. In addition, whereas
TWIST1 TQS phosphorylation was required for prostate cancer
metastasis in vivo, TQS phosphorylation was not absolutely required for
limb development in mice. In agreement with our findings, T-E
tethered heterodimers have been reported to activate transcription from
a Tinman reporter, whereas tethered homodimers T-T and E12-E12
homodimers had no activity in this assay [6]. These contrasting findings
between embryonic development and cancer metastasis studies suggest
that TWIST1 TQS phosphorylation can result in different functional
consequences depending on the context. In support of this concept are
in vivo data showing that T-T and T-E complexes have antagonistic
downstream effects on fibroblast growth factor signaling that determine
cranial suture patency [35,39]. Given these likely context-specific
differences of TWIST1 biology, it should not be assumed that PKA
phosphorylates the TWIST1 TQS motif in general for all contexts.
Protein kinase C [36], as well other serine threonine kinases such as
Rho-associated protein kinases, Protein kinase G (PKG) and other
members of the protein kinase C family can also phosphorylate related
Hand transcription factors [40]. The TWIST1 TQS motif may also be
phosphorylated by Akt [38]. Indeed, our pharmacologic data with the
specific PI3K-mTOR dual kinase inhibitor, BEZ235, suggest that
phosphorylation of theTWIST1TQSmotif by the PI3K-AKT-mTOR
pathway is required for TWIST1-induced cell migration. Furthermore,
BEZ235 treatment of Myc-CaP cells overexpressing tethered isoforms
of TWIST1 suggests that TQS phosphorylation is important to direct
T-E heterodimerization. These pharmacologic data need to be validated
with complimentary assays in other cancer cell types. Finally, it is worth
reiterating that other regulatory mechanisms also influence TWIST1
dimeric partner choice, such as the relative levels of TWIST1, ID, and
E-proteins.
Equally important are the protein phosphatases that would act to
limit TWIST1 metastatic potential. Protein phosphatase 2A (PP2A)
containing the B56 delta regulatory subunit has been identified as sucha factor [31,36]. PP2A activity counteracts a number of kinase
pathways associated with development of cancer and is often
functionally inactivated in many tumors [41]. The large published
data set supporting an anti-cancer role for PP2A further supports our
conclusions that phosphorylated TWIST1 is mediating advancement
of metastatic disease.
The general role of TWIST1 posttranslational modifications in
cancer-related functions, predominantly breast cancer, has only
recently been appreciated. Hyaluronic acid binding to CD44
promotes c-Src kinase Twist phosphorylation that results in Twist
nuclear translocation and transcriptional activation in breast cancer
cells leading to increased cellular invasion [42]. Breast tumor cell
EMT and cellular invasion can also be increased through p38, c-Jun
N-terminal kinase, and extracellular signal–regulated kinase 1/2
phosphorylation of Twist1 at Ser68 that results in Twist1 protein
stabilization [43]. Lastly, in response to Interleukin 6 (IL-6)
stimulation, Twist stability is also regulated at the posttranslational
level in head and neck squamous cell carcinomas through casein kinase
2 phosphorylation of Twist on residues Ser18 and Ser20 [44]. TWIST1
phosphorylation on Ser42 by Akt has been shown to promote EMTand
metastasis of breast cancer cells in vivo. Akt phosphorylation of Twist1
Ser42 promotes metastasis by transcriptional up-regulation of
transforming growth factor–β2 [45]. Akt phosphorylation of Twist1
Ser42 has also been shown to confer cell death resistance to DNA
damage through inhibition of a p53-dependent pathway [46]. In this
study, we extend these previous findings, showing that the PI3K-AKT-
mTOR pathway is required for TQSmotif phosphorylation and can be
inhibited by BEZ235 in prostate cancer cells. Thus, our current study is
in agreement with the notion that posttranslational modifications of
TWIST1 have functional consequences in cancer and extend these
general findings to prostate cancer.
Importantly, our study shows for the first time the requirement of
the PI3K-AKT-mTOR pathway for TQS motif phosphorylation,
which is required for the pro-metastatic functions of TWIST1 in
prostate cancer cells in vitro and in vivo.
TWIST1 and Twist1 protein expression levels are correlated with
prostate cancer metastasis and clinical factors associated with
lethal disease [12,16,17]. In addition to being a biomarker of
aggressive prostate cancer, Twist1 inhibition may also be a potential
novel therapeutic strategy for prostate cancer treatment. Inactiva-
tion of Twist1 to only physiological levels may be sufficient for anti-
cancer effects [20,47–49], and the very limited expression of
TWIST1 in normal tissues in the adult mouse suggests that
targeting TWIST1 systemically is well tolerated [50]. However,
transcription factors have traditionally been difficult to inhibit
directly [51]. Our findings suggest that PI3K-AKT-mTOR
pathway inhibition with the dual kinase inhibitor BEZ235 may
be an attractive indirect approach to target TWIST1-induced pro-
metastatic phenotypes. In addition, we observed using both
androgen-dependent and androgen-independent cell line models
that the major pro-metastatic effects of TWIST1 are independent of
the androgen receptor influence on prostate cancer cells. Interest-
ingly, the T-E heterodimer has recently been shown to possess a
unique cavity that can be specifically targeted by intercalating
molecules for inhibitory purposes [52]. Our study also demon-
strates the TQS motif as a critical structural component required for
TWIST1-dependent pro-metastatic functions in prostate cancer
and points toward targeting the T-E heterodimer as another
tractable alternative therapeutic strategy.
Figure 8. BEZ235 inhibition of PI3K-mTOR kinases prevents TWIST1-induced prostate cancer cell migration. (A) Representative phase
contrast images of Myc-CaP cells overexpressing TWIST1 and TWIST1 phospho-mutants that have been treated with 10 nM BEZ235 for
24 hours, then a wound scratch was performed and then 24 hours after wound scratch. (B) Relative wound closure is calculated by the
remaining wound area normalized to the initial wound area [n≥ 3 experiments with three fields per experiment by ImageJ software (NIH)]
and showed that BEZ235 treatment only inhibited the migration of Myc-CaP cells overexpressing TWIST1. (C) The relative inhibitory effect
of BEZ235 on cell migration was determined by normalizing the migratory potential of untreated cells to that of 10 nM BEZ235-treated
cells. Mann-Whitney test: **P b .01.
Neoplasia Vol. 17, No. 1, 2015 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. 29
30 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. Neoplasia Vol. 17, No. 1, 2015Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.10.009.
References
[1] Siegel R, Naishadham D, and Jemal A (2013). Cancer statistics, 2013. CA Cancer
J Clin 63(1), 11–30.
[2] Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, and Walsh PC
(1999). Natural history of progression after PSA elevation following radical
prostatectomy. JAMA 281(17), 1591–1597.
[3] Thiery JP, Acloque H, Huang RY, and Nieto MA (2009). Epithelial-
mesenchymal transitions in development and disease. Cell 139(5), 871–890.
[4] Spicer DB, Rhee J, Cheung WL, and Lassar AB (1996). Inhibition of myogenic
bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 272
(5267), 1476–1480.
[5] Lee YM, Park T, Schulz RA, and Kim Y (1997). Twist-mediated activation of the
NK-4 homeobox gene in the visceral mesoderm of Drosophila requires two distinct
clusters of E-box regulatory elements. J Biol Chem 272(28), 17531–17541.
[6] Laursen KB, Mielke E, Iannaccone P, and Fuchtbauer EM (2007). Mechanism
of transcriptional activation by the proto-oncogene Twist1. J Biol Chem 282(48),
34623–34633.
[7] QinQ, Xu Y,He T, Qin C, and Xu J (2012). Normal and disease-related biological
functions of Twist1 and underlying molecular mechanisms.Cell Res 22(1), 90–106.
[8] Ansieau S, Morel AP, Hinkal G, Bastid J, and Puisieux A (2010). TWISTing an
embryonic transcription factor into an oncoprotein. Oncogene 29(22), 3173–3184.
[9] Barnes RM and Firulli AB (2009). A twist of insight—the role of Twist-family
bHLH factors in development. Int J Dev Biol 53(7), 909–924.
[10] el Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D,
Bourgeois P, Bolcato-Bellemin AL, Munnich A, and Bonaventure J (1997).
Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 15
(1), 42–46.
[11] Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI,
Garcia Delgado C, Gonzalez-Ramos M, Kline AD, and Jabs EW (1997).
Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-
Chotzen syndrome. Nat Genet 15(1), 36–41.
[12] Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan
KW, Chan FL, Glackin C, Wong YC, and Wang X (2005). Up-regulation of
TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res
65(12), 5153–5162.
[13] Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M,
Uchiumi T, and Naito S (2010). Castration resistance of prostate cancer cells
caused by castration-induced oxidative stress through Twist1 and androgen
receptor overexpression. Oncogene 29(2), 237–250.
[14] Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L,
Zhang H, Chen H, Sun X, Boothman DA, Min W, and Hsieh JT (2010). Role
of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate
cancer metastasis. Proc Natl Acad Sci U S A 107(6), 2485–2490.
[15] Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A,
and Gleave ME (2012). Clusterin mediates TGF-β-induced epithelial-
mesenchymal transition and metastasis via Twist1 in prostate cancer cells.
Cancer Res 72(20), 5261–5272.
[16] Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R,
Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns
TF, Chung CH, Rudin CM, Herman JM, Hales RK, Raman V, An SS, and Tran
PT (2013). The Twist box domain is required for Twist1-induced prostate
cancer metastasis. Mol Cancer Res 11(11), 1387–1400.
[17] Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, and Chan KW (2007).
Significance of TWIST and E-cadherin expression in the metastatic progression
of prostatic cancer. Histopathology 50(5), 648–658.
[18] Yuen HF, Kwok WK, Chan KK, Chua CW, Chan YP, Chu YY, Wong YC,
Wang X, and Chan KW (2008). TWIST modulates prostate cancer cell-
mediated bone cell activity and is upregulated by osteogenic induction.
Carcinogenesis 29(8), 1509–1518.
[19] Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, and Sawyers
CL (2005). Context-dependent hormone-refractory progression revealed
through characterization of a novel murine prostate cancer cell line. Cancer Res
65(24), 11565–11571.[20] Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J,
Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH,
Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, and Felsher DW (2012).
Twist1 suppresses senescence programs and thereby accelerates and maintains
mutant Kras-induced lung tumorigenesis. PLoS Genet 8(5), e1002650.
[21] Firulli BA, Redick BA, Conway SJ, and Firulli AB (2007). Mutations within
helix I of Twist1 result in distinct limb defects and variation of DNA binding
affinities. J Biol Chem 282(37), 27536–27546.
[22] Butler JP, Tolic-Norrelykke IM, Fabry B, and Fredberg JJ (2002). Traction
fields, moments, and strain energy that cells exert on their surroundings. Am J
Physiol 282(3), C595–C605.
[23] Wang N, Tolic-Norrelykke IM, Chen J, Mijailovich SM, Butler JP, Fredberg JJ,
and Stamenovic D (2002). Cell prestress. I. Stiffness and prestress are closely
associated in adherent contractile cells. Am J Physiol 282(3), C606–C616.
[24] Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP,
Schwartz LH, Miller VA, Kawashima T, Kitamura T, Paik D, and Felsher DW
(2011). Survival and death signals can predict tumor response to therapy after
oncogene inactivation. Sci Transl Med 3(103), 03ra99.
[25] Fiucci G, Ravid D, Reich R, and Liscovitch M (2002). Caveolin-1 inhibits
anchorage-independent growth, anoikis and invasiveness in MCF-7 human
breast cancer cells. Oncogene 21(15), 2365–2375.
[26] Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen
J, Terezakis S, Kleinberg L, Redmond K, Hales RK, Salvatori R, Quinones-
Hinojosa A, Tran PT, and Lim M (2011). Nelfinavir induces radiation
sensitization in pituitary adenoma cells. Cancer Biol Ther 12(7), 657–663.
[27] Zhou G,Wang S, Wang Z, Zhu X, Shu G, LiaoW, Yu K, Gao P, Xi Q,Wang X,
Zhang Y, Yuan L, and Jiang Q (2010). Global comparison of gene expression
profiles between intramuscular and subcutaneous adipocytes of neonatal landrace
pig using microarray. Meat Sci 86(2), 440–450.
[28] Carvalho BS and Irizarry RA (2010). A framework for oligonucleotide microarray
preprocessing. Bioinformatics 26(19), 2363–2367.
[29] Benjamini Y, Drai D, Elmer G, Kafkafi N, andGolani I (2001). Controlling the false
discovery rate in behavior genetics research. Behav Brain Res 125(1–2), 279–284.
[30] Firulli AB and Conway SJ (2008). Phosphoregulation of Twist1 provides a
mechanism of cell fate control. Curr Med Chem 15(25), 2641–2647.
[31] Firulli BA, Krawchuk D, Centonze VE, Vargesson N, Virshup DM, Conway SJ,
Cserjesi P, Laufer E, and Firulli AB (2005). Altered Twist1 and Hand2
dimerization is associated with Saethre-Chotzen syndrome and limb abnormal-
ities. Nat Genet 37(4), 373–381.
[32] Chaffer CL and Weinberg RA (2011). A perspective on cancer cell metastasis.
Science 331(6024), 1559–1564.
[33] Price JE (2001). Xenograft models in immunodeficient animals: I. Nude mice:
spontaneous and experimental metastasis models.Methods Mol Med 58, 205–213.
[34] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, and Mesirov JP (2005). Gene
set enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A 102(43), 15545–15550.
[35] Connerney J, Andreeva V, Leshem Y, Mercado MA, Dowell K, Yang X, Lindner
V, Friesel RE, and Spicer DB (2008). Twist1 homodimers enhance FGF
responsiveness of the cranial sutures and promote suture closure.Dev Biol 318(2),
323–334.
[36] Castanon I and Baylies MK (2002). A Twist in fate: evolutionary comparison of
Twist structure and function. Gene 287(1–2), 11–22.
[37] Firulli BA, Howard MJ, McDaid JR, McIlreavey L, Dionne KM, Centonze VE,
Cserjesi P, Virshup DM, and Firulli AB (2003). PKA, PKC, and the protein
phosphatase 2A influence HAND factor function: a mechanism for tissue-
specific transcriptional regulation. Mol Cell 12(5), 1225–1237.
[38] Lu S, Nie J, Luan Q, Feng Q, Xiao Q, Chang Z, Shan C, Hess D, Hemmings
BA, and Yang Z (2011). Phosphorylation of the Twist1-family basic helix-loop-
helix transcription factors is involved in pathological cardiac remodeling. PLoS
One 6(4), e19251.
[39] Connerney J, Andreeva V, Leshem Y, Muentener C, Mercado MA, and Spicer
DB (2006). Twist1 dimer selection regulates cranial suture patterning and fusion.
Dev Dyn 235(5), 1345–1357.
[40] Kennelly PJ and Krebs EG (1991). Consensus sequences as substrate specificity
determinants for protein kinases and protein phosphatases. J Biol Chem 266(24),
15555–15558.
[41] Perrotti D and Neviani P (2013). Protein phosphatase 2A: a target for anticancer
therapy. Lancet Oncol 14(6), e229–e238.
Neoplasia Vol. 17, No. 1, 2015 TWIST1 TQS motif in prostate cancer metastasis Gajula et al. 31[42] Bourguignon LY,WongG, Earle C, Krueger K, and Spevak CC (2010). Hyaluronan-
CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expres-
sion, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton
activation and breast tumor cell invasion. J Biol Chem 285(47), 36721–36735.
[43] Hong J, Zhou J, Fu J, He T, Qin J, Wang L, Liao L, and Xu J (2011).
Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and
promotes breast cancer cell invasiveness. Cancer Res 71(11), 3980–3990.
[44] Su YW, Xie TX, Sano D, and Myers JN (2011). IL-6 stabilizes Twist and
enhances tumor cell motility in head and neck cancer cells through activation of
casein kinase 2. PLoS One 6(4), e19412.
[45] Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, Ruegg C, and
Hemmings BA (2012). Akt/PKB-mediated phosphorylation of Twist1 promotes
tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β
signaling axes. Cancer Discov 2(3), 248–259.
[46] Vichalkovski A, Gresko E, Hess D, Restuccia DF, and Hemmings BA (2010).
PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits
p53 activity in response to DNA damage. Oncogene 29(24), 3554–3565.
[47] Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN,
Aziz K, Cho YJ, Tran PT, and Rudin CM (2013). Inhibition of TWIST1 leads toactivation of oncogene-induced senescence in oncogene-driven non-small cell lung
cancer.Mol Cancer Res 11(4), 329–338.
[48] Kwok WK, Ling MT, Yuen HF, Wong YC, and Wang X (2007). Role of
p14ARF in TWIST-mediated senescence in prostate epithelial cells. Carcino-
genesis 28(12), 2467–2475.
[49] Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F,
Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-
Wittmann S, Caron de Fromentel C, and Puisieux A (2008). Induction of EMT
by twist proteins as a collateral effect of tumor-promoting inactivation of
premature senescence. Cancer Cell 14(1), 79–89.
[50] Pan D, Fujimoto M, Lopes A, and Wang YX (2009). Twist-1 is a PPARdelta-
inducible, negative-feedback regulator of PGC-1alpha in brown fat metabolism.
Cell 137(1), 73–86.
[51] Verdine GL and Walensky LD (2007). The challenge of drugging undruggable
targets in cancer: lessons learned from targeting BCL-2 family members. Clin
Cancer Res 13(24), 7264–7270.
[52] Bouard C, Terreux R, Hope J, Chemelle JA, Puisieux A, Ansieau S, and Payen L
(2014). Interhelical loops within the bHLH domain are determinant in
maintaining TWIST1-DNA complexes. J Biomol Struct Dyn 32(2), 226–241.
